Jianqin Hu, Jingxue Lai, Bing Zhang, Xuanfei Jiang, H F Ma, Y H Liu
5 min
Alzheimer's disease (AD) is traditionally defined by the accumulation of beta-amyloid (Aβ) plaques and phosphorylated tau (p-tau) neurofibrillary tangles. However, recent research highlights that mitochondrial dysfunction is a critical, early-stage driver of the disease. Mitochondria are not merely energy producers; they are central processors of cellular information and homeostasis. In AD, mitochondrial bioenergetic deficits—such as impaired oxidative phosphorylation (OXPHOS) and reduced ATP production—interact synergistically with Aβ and tau. This creates a self-reinforcing vicious cycle where oxidative stress, calcium dysregulation, and impaired mitophagy (the clearance of damaged mitochondria) accelerate neurodegeneration.
Neuroimaging has emerged as a powerful, noninvasive approach to map these pathological dynamics. Researchers are now using multimodal imaging to bridge the gap between microscopic molecular events and macroscopic brain changes:
Traditional therapeutic approaches targeting only Aβ have shown limited clinical success, often failing to halt cognitive decline. By identifying mitochondrial dysfunction as a central node in the AD pathological network, researchers are shifting toward a more holistic strategy. Integrating mitochondrial mechanism research with advanced neuroimaging allows for earlier detection, more precise patient stratification, and objective monitoring of novel therapies that aim to restore redox balance, improve energy metabolism, or enhance mitochondrial quality control. This multimodal approach is essential for moving toward precision medicine in the treatment of Alzheimer's disease.
Alzheimer’s disease (AD), primarily characterized by progressive cognitive decline, poses a significant global public health challenge. Emerging evidence indicates that mitochondrial dysfunction plays a central role in AD-related neurodegeneration. This dysfunction manifests as impaired energy metabolism and elevated oxidative stress, and it interacts with β-amyloid (Aβ) and phosphorylated tau (p-tau) pathologies, collectively forming a self-reinforcing vicious cycle. This review systematically explores the mechanisms underlying mitochondrial dysfunction in AD and highlights recent advancements in neuroimaging technologies, such as positron emission tomography (PET), magnetic resonance spectroscopy (MRS), and susceptibility-weighted imaging (SWI), for detecting mitochondrial abnormalities and metabolic disturbances. These multimodal imaging modalities enable the in vivo assessment of mitochondrial metabolism, oxidative stress levels, iron deposition, and the integrity of neural networks. Such capabilities not only enhance our understanding of the spatiotemporal progression of mitochondrial pathology in AD but also offer novel tools for early diagnosis, precise patient stratification, and objective evaluation of therapeutic efficacy. Accordingly, this review evaluates the substantial potential of integrating mitochondrial mechanism research with neuroimaging technologies in both foundational research and clinical practice related to AD.
Sam: [nodding, acknowledging the point] You're right on both counts. On resolution: phosphorus-31 spectroscopy is the gold standard for measuring metabolic flux directly, but it has low sensitivity and needs long scan times, which makes it impractical outside a research setting. Proton magnetic resonance spectroscopy can track antioxidant levels like glutathione, but again, that's a research tool, not something built for a memory clinic. And on causality — the review is honest that this is a case built from converging evidence across imaging, biochemistry, and cell models, not a single intervention study that isolates mitochondrial failure as the first domino. That's a real gap.
Alex: [thought-provoking, reflective] So there's a mismatch: we have high-resolution tools to see plaques, but nothing standardized enough to map the metabolic failure that may be causing them, at the scale you'd need for a clinical trial. [[RP_SECTION:mitochondrial-dynamics-and-fission|Mitochondrial dynamics and fission]]
Sam: [measured, settling the point] That's precisely the constraint the field is trying to work around, by fusing metabolic imaging with structural scans rather than replacing one with the other. There's also a structural piece to this beyond the biochemistry — mitochondrial dynamics. Amyloid and p-tau hyperactivate a protein called Drp1, which drives excessive fission. You end up with mitochondria that fragment faster than the cell's quality-control system, mitophagy, can clear them. So damaged organelles pile up rather than getting recycled, which is its own separate route into the same energy crisis.
Alex: [analytical, even pace] So you've got the biochemical loop — oxidative stress and misfolding reinforcing each other — and a parallel structural collapse in how the cell manages its damaged mitochondria. That's two independent points of failure feeding one outcome. Is there anywhere in that system a therapeutic could actually intervene, given how tangled the loop is? [[RP_SECTION:therapeutic-intervention-strategies|Therapeutic intervention strategies]]
Sam: [measured, settling the point] The review's position is that intervention has to happen before the loop closes — targeting mitophagy or the fission-fusion balance while the mitochondrial signal is still detectable but plaques haven't formed yet. That points toward patients in mild cognitive impairment, using metabolic markers to find people who are mid-crisis rather than waiting for a structural diagnosis. But that's a proposal for where to look, not a validated biomarker with an established cutoff or a trial behind it yet.
Alex: [concluding, analytical] Which means the real next step isn't better imaging resolution on its own — it's establishing whether these metabolic markers actually predict the rate of decline. Without that validation, you can't design a trial around them with any confidence.
Sam: [steady] That's exactly the open question the review leaves on the table. The figures, the imaging comparisons, and the caveats around each technique are laid out in more detail than we've covered here — you can generate a deep dive of this paper if you want to sit with them, and the paper itself has the rest either way.
Alex: Thanks for listening.